Veradermics, Incorporated MANE
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T15:27:06.574Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:25:57.861493571Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T15:27:06.301019+00:00
Veradermics, Incorporated options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 173.13 | 100.6% | 17.6% | 137.74 | 64.4% | 8.9% |
| 25Δ | 164.19 | 78.5% | 11.7% | 140.41 | 63.0% | 7.5% |
| 30Δ | 161.38 | 75.0% | 10.2% | 142.51 | 62.1% | 6.5% |
| 35Δ | 158.57 | 71.5% | 8.7% | 144.61 | 61.3% | 5.5% |
| 40Δ | 155.76 | 67.9% | 7.2% | 146.50 | 62.7% | 4.9% |
| 45Δ | 152.96 | 64.4% | 5.7% | 148.36 | 64.6% | 4.3% |
| 50Δ | 150.15 | 60.9% | 4.2% | 150.23 | 66.2% | 3.8% |
| 55Δ | 148.29 | 60.8% | 3.6% | 152.25 | 66.3% | 3.3% |
| 60Δ | 146.48 | 61.0% | 3.0% | 154.28 | 66.4% | 2.7% |
| 65Δ | 144.61 | 61.3% | 2.5% | 156.12 | 64.5% | 2.2% |
| 70Δ | 142.47 | 62.4% | 2.1% | 157.87 | 61.4% | 1.7% |
| 75Δ | 140.34 | 63.6% | 1.7% | 159.62 | 58.4% | 1.2% |
| 80Δ | 137.86 | 63.7% | 1.3% | 161.84 | 56.6% | 0.9% |
20Δ
- Pseudo strike
- 173.13
- IV
- 100.6%
- B/E move
- 17.6%
- Pseudo strike
- 137.74
- IV
- 64.4%
- B/E move
- 8.9%
25Δ
- Pseudo strike
- 164.19
- IV
- 78.5%
- B/E move
- 11.7%
- Pseudo strike
- 140.41
- IV
- 63.0%
- B/E move
- 7.5%
30Δ
- Pseudo strike
- 161.38
- IV
- 75.0%
- B/E move
- 10.2%
- Pseudo strike
- 142.51
- IV
- 62.1%
- B/E move
- 6.5%
35Δ
- Pseudo strike
- 158.57
- IV
- 71.5%
- B/E move
- 8.7%
- Pseudo strike
- 144.61
- IV
- 61.3%
- B/E move
- 5.5%
40Δ
- Pseudo strike
- 155.76
- IV
- 67.9%
- B/E move
- 7.2%
- Pseudo strike
- 146.50
- IV
- 62.7%
- B/E move
- 4.9%
45Δ
- Pseudo strike
- 152.96
- IV
- 64.4%
- B/E move
- 5.7%
- Pseudo strike
- 148.36
- IV
- 64.6%
- B/E move
- 4.3%
50Δ
- Pseudo strike
- 150.15
- IV
- 60.9%
- B/E move
- 4.2%
- Pseudo strike
- 150.23
- IV
- 66.2%
- B/E move
- 3.8%
55Δ
- Pseudo strike
- 148.29
- IV
- 60.8%
- B/E move
- 3.6%
- Pseudo strike
- 152.25
- IV
- 66.3%
- B/E move
- 3.3%
60Δ
- Pseudo strike
- 146.48
- IV
- 61.0%
- B/E move
- 3.0%
- Pseudo strike
- 154.28
- IV
- 66.4%
- B/E move
- 2.7%
65Δ
- Pseudo strike
- 144.61
- IV
- 61.3%
- B/E move
- 2.5%
- Pseudo strike
- 156.12
- IV
- 64.5%
- B/E move
- 2.2%
70Δ
- Pseudo strike
- 142.47
- IV
- 62.4%
- B/E move
- 2.1%
- Pseudo strike
- 157.87
- IV
- 61.4%
- B/E move
- 1.7%
75Δ
- Pseudo strike
- 140.34
- IV
- 63.6%
- B/E move
- 1.7%
- Pseudo strike
- 159.62
- IV
- 58.4%
- B/E move
- 1.2%
80Δ
- Pseudo strike
- 137.86
- IV
- 63.7%
- B/E move
- 1.3%
- Pseudo strike
- 161.84
- IV
- 56.6%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 56.54% | |
| 57.72% | |
| 58.50% | |
| 59.84% | |
| 59.54% | |
| 60.51% | |
| 58.28% | |
| 57.58% | |
| 58.10% | |
| 61.06% |
Biotechnology
MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic…
More →MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and…
More →MCRB
Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host…
More →MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of…
More →MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered…
More →MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
More →